Key result
Saracatinib curbs plaque inflammation and slows atherosclerosis progression across preclinical translational models.
Answers are grounded in this paper and cite their sources.
The development of new immunotherapies to treat the inflammatory mechanisms that sustain atherosclerotic cardiovascular disease (ASCVD) is urgently needed. Herein, we present a path to drug repurposing to identify immunotherapies for ASCVD. The integration of time-of-flight mass cytometry and RNA sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. Ex vivo screens, using human samples, showed that saracatinib—a phase 2a-ready SRC and ABL inhibitor—reversed the inflammatory responses induced by ASCVD plasma. In Apoe −/− mice, saracatinib reduced atherosclerosis progression by reprogramming reparative macrophages. In a rabbit model of advanced atherosclerosis, saracatinib reduced plaque inflammation measured by [ 18 F]fluorodeoxyglucose positron emission tomography–magnetic resonance imaging. Here we show a systems immunology-driven drug repurposing with a preclinical validation strategy to aid the development of cardiovascular immunotherapies.
No takes yet. Share an insight, caveat, or question.
Amadori et al. (2023) studied Atherosclerotic cardiovascular disease (ASCVD). Saracatinib was evaluated on Atherosclerosis progression and plaque inflammation. Saracatinib reversed ASCVD plasma-induced inflammation ex vivo, reduced atherosclerosis progression in mice, and reduced plaque inflammation in a rabbit model of advanced atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: